These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20016048)

  • 21. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
    Mehta RV; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain.
    Golbahar J; Al-Ayadhi M; Das NM; Gumaa K
    Int J Womens Health; 2012; 4():201-6. PubMed ID: 22654525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome.
    Dambala K; Vavilis D; Bili E; Goulis DG; Tarlatzis BC
    Gynecol Endocrinol; 2017 Jul; 33(7):529-533. PubMed ID: 28300464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The predictive power of endocrine tests for the diagnosis of polycystic ovaries in women with oligoamenorrhea.
    Turhan NO; Toppare MF; Seçkin NC; Dilmen G
    Gynecol Obstet Invest; 1999; 48(3):183-6. PubMed ID: 10545743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome.
    Nadaraja RND; Sthaneshwar P; Razali N
    Malays J Pathol; 2018 Apr; 40(1):33-39. PubMed ID: 29704382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
    Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome.
    Livadas S; Pappas C; Karachalios A; Marinakis E; Tolia N; Drakou M; Kaldrymides P; Panidis D; Diamanti-Kandarakis E
    Endocrine; 2014 Nov; 47(2):631-8. PubMed ID: 24752393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of growth hormone suppression on the serum levels of ovarian and adrenal sex steroid hormones in normal women and in women with polycystic ovary syndrome.
    Takeuchi T; Kawana T
    Gynecol Endocrinol; 1997 Oct; 11(5):307-13. PubMed ID: 9385529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
    Yildiz BO; Yarali H; Oguz H; Bayraktar M
    J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of luteinizing hormone and insulin on sex steroids and sex hormone-binding globulin in the polycystic ovarian syndrome.
    Buyalos RP; Geffner ME; Watanabe RM; Bergman RN; Gornbein JA; Judd HL
    Fertil Steril; 1993 Oct; 60(4):626-33. PubMed ID: 8405515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome.
    Mu L; Pan J; Yang L; Chen Q; Chen Y; Teng Y; Wang P; Tang R; Huang X; Chen X; Yang H
    Reprod Biol Endocrinol; 2018 Oct; 16(1):104. PubMed ID: 30359269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.
    Pigny P; Jonard S; Robert Y; Dewailly D
    J Clin Endocrinol Metab; 2006 Mar; 91(3):941-5. PubMed ID: 16368745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.